HomeCompareENDP vs PLD

ENDP vs PLD: Dividend Comparison 2026

ENDP yields 534.19% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENDP wins by $102777.37M in total portfolio value
10 years
ENDP
ENDP
● Live price
534.19%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102783.28M
Annual income
$75,120,205,270.55
Full ENDP calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ENDP vs PLD

📍 ENDP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENDPPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENDP + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENDP pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENDP
Annual income on $10K today (after 15% tax)
$45,405.98/yr
After 10yr DRIP, annual income (after tax)
$63,852,174,479.97/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, ENDP beats the other by $63,848,136,363.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENDP + PLD for your $10,000?

ENDP: 50%PLD: 50%
100% PLD50/50100% ENDP
Portfolio after 10yr
$51394.59M
Annual income
$37,562,477,997.87/yr
Blended yield
73.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ENDP
Analyst Ratings
24
Buy
20
Hold
4
Sell
Consensus: Buy
Price Target
$2.00
+434.2% upside vs current
Range: $2.00 — $2.00
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENDP buys
0
PLD buys
0
No recent congressional trades found for ENDP or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENDPPLD
Forward yield534.19%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$102783.28M$5.91M
Annual income after 10y$75,120,205,270.55$4,750,725.19
Total dividends collected$100415.31M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$2.00$136.00

Year-by-year: ENDP vs PLD ($10,000, DRIP)

YearENDP PortfolioENDP Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$64,119$53,418.80$11,241$540.96+$52.9KENDP
2$388,715$320,107.45$13,019$991.13+$375.7KENDP
3$2,229,591$1,813,666.47$15,801$1,870.97+$2.21MENDP
4$12,107,940$9,722,278.04$20,609$3,701.21+$12.09MENDP
5$62,298,925$49,343,428.51$29,919$7,867.97+$62.27MENDP
6$303,936,946$237,277,096.11$50,631$18,617.74+$303.89MENDP
7$1,407,082,298$1,081,869,766.45$105,528$51,352.20+$1406.98MENDP
8$6,186,454,865$4,680,876,806.01$287,364$174,449.42+$6186.17MENDP
9$25,853,337,136$19,233,830,430.18$1,081,760$774,280.77+$25852.26MENDP
10$102,783,276,006$75,120,205,270.55$5,908,209$4,750,725.19+$102777.37MENDP

ENDP vs PLD: Complete Analysis 2026

ENDPStock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full ENDP Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ENDP vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENDP vs SCHDENDP vs JEPIENDP vs OENDP vs KOENDP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.